Operating
Stock-Based Comp
Amgen Stock-Based Comp decreased by 1.6% to $125.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 6.7%, from $134.00M to $125.00M. Over 4 years (FY 2021 to FY 2025), Stock-Based Comp shows an upward trend with a 9.7% CAGR.
Analysis
StatementCash Flow Statement
SectionOperating
CategoryCapital Allocation
SignalContext dependent
VolatilityModerate
First reportedQ4 2013
Last reportedQ4 2025
How to read this metric
An increase may signal a strategy to preserve cash or align employee interests with shareholders, but it also results in share dilution.
Detailed definition
Stock-based compensation is a non-cash expense where employees and executives are rewarded with equity or stock options...
Peer comparison
High-growth technology firms often have higher stock-based compensation as a percentage of revenue compared to mature industrial firms.
Metric ID:
cf_stock_based_compensationHistorical Data
19 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $85.25M | $85.25M | $85.25M | $100.25M | $100.25M | $100.25M | $100.25M | $47.00M | $119.00M | $104.00M | $161.00M | $103.00M | $157.00M | $136.00M | $134.00M | $85.00M | $157.00M | $127.00M | $125.00M |
| QoQ Change | — | +0.0% | +0.0% | +17.6% | +0.0% | +0.0% | +0.0% | -53.1% | +153.2% | -12.6% | +54.8% | -36.0% | +52.4% | -13.4% | -1.5% | -36.6% | +84.7% | -19.1% | -1.6% |
| YoY Change | — | — | — | — | +17.6% | +17.6% | +17.6% | -53.1% | +18.7% | +3.7% | +60.6% | +119.1% | +31.9% | +30.8% | -16.8% | -17.5% | +0.0% | -6.6% | -6.7% |
Range$47.00M – $161.00M
CAGR+8.9%
Avg YoY Growth+14.5%
Median YoY Growth+17.6%
Current Streak2 quarters decline
Stock-Based Comp at Other Companies
Frequently Asked Questions
- What is Amgen's stock-based comp?
- Amgen (AMGN) reported stock-based comp of $125.00M in Q4 2025.
- How has Amgen's stock-based comp changed year-over-year?
- Amgen's stock-based comp decreased by 6.7% year-over-year, from $134.00M to $125.00M.
- What is the long-term trend for Amgen's stock-based comp?
- Over 4 years (2021 to 2025), Amgen's stock-based comp has grown at a 9.7% compound annual growth rate (CAGR), from $341.00M to $494.00M.
- What does stock-based comp mean?
- The value of company shares given to employees as part of their pay.